

Nanomedicine Map reveals the European landscape and potential as never seen before

Click here to [Explore the European nanomedicine community](#)

Paris, France – Tuesday December 10th, 2013 –Initiated by the European project NANOMED2020 whose core mission is to federate the nanomedicine community, the newly released Map provides thorough insights into the existing nanomedicine community by introducing on a single chart all the ecosystem’s actors in Europe and beyond. This reference tool aims at increasing awareness, providing new networking opportunities, and at initiating fruitful partnerships.

Overall, more than **500 industrial players and SMEs** having a direct link or activity with the field have been identified, together with **nearly a thousand actors conducting research of excellence** across Europe in Laboratories or Research Centres.

With the NanoMed Map, the nanomedicine community wins its own exploration tool displaying the **top 1500 European actors in the field of nanomedicine**, ranging from research centres and academia to SMEs and industries, from associations and clusters to healthcare providers, public and funding authorities. Such exhaustive mapping wouldn’t have been possible without extensive collaborations over the past nine months, surveys consolidations, online data and literature review.

The intrinsic value of such feature does not reside only in the many dots on the map, but in the detailed and easily accessible information about the actors’ research activities, products, areas of activities and specific transversal expertise. This Nanomed Map is therefore a real instrument for any nanomedicine enthusiast to find the right contact or partner for collaborative work.

Olivier Fontaine, responsible of the mapping activity under NANOMED2020, stated: *“We are very proud to finally release the first European Nanomedicine Map, the result of significant work and scrutiny led by the NANOMED2020 Consortium. We now invite the nanomedicine actors to navigate through the map and eventually amend or add their entries. This feedback is crucial to guarantee an up-to-date dynamic tool for the community and the national authorities and to raise awareness among the general public.”*

As a leading nanomedicine SME, Nanobiotix actively contributed to such exhaustive exercise by its deep understanding and knowledge of the whole ecosystem and by providing a key network of dedicated pharmaceutical companies actively involved in the field.

“Beyond showing the European potential and leadership, the Nanomed Map has an outstanding potential to lay the ground for the future of nanomedicine in Europe. It is an essential step towards a more competitive and structured industrial landscape in the field”, said Laurent Levy, CEO of Nanobiotix and partner of NANOMED2020.

Explore the –not so small – European nanomedicine community on the ETPN website at:
<http://www.etp-nanomedicine.eu/public/european-nanomedicine-map>



-----ENDS-----

About ETPN

The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.

For more information, visit www.etp-nanomedicine.eu.

The renewed list of recognised ETPs is publically available on the European Commission's ETP website: http://cordis.europa.eu/technology-platforms/individual_en.html.

About NANOMED2020



NANOMED2020 is a Coordination and Support Action under the FP7-Health aiming at delivering concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020.

The project started one year ago, with key activities focusing on 1) federating the nanomedicine community and 2) identifying the gaps and needs towards an efficient translation of excellent research into more and innovative products onto the market in Europe.

The Nanomedicine Map, the Nanomedicine Award, the pan-European event Nano World Cancer Day and the White Paper "Contributions of Nanomedicine to Horizon 2020" (<http://www.etp-nanomedicine.eu/etpn-white-paper-2013>) are notable outcomes of such activities.

The project involves seven partners across Europe including the ETPN Secretariat, the CLINAM foundation (Switzerland), the National Institute of Health Carlos III (Spain), Bioanalytik-muenster e.V (Germany), Nanobiotix SA (France), the Fondazione Don Carlo Gnocchi ONLUS (Italy), and SINTEF (Norway).

For more information, visit <http://www.etp-nanomedicine.eu/nanomed2020/public>

About NANOBIOTIX - www.nanobiotix.com



Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current

radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Contacts

ETPN | Olivier Fontaine and Nicolas Gouze

secretariat@etp-nanomedicine.eu

Nanobiotix

Sarah Gaubert

Head of Communication

and Public Affairs

+33 (0)1 40 26 07 55

contact@nanobiotix.com

NewCap.

*Financial communication
and investors relations*

Louis-Victor Delouvier / Emmanuel Huynh

+33 (0)1 44 71 98 53

lvdelouvier@newcap.fr

Yucatan

Media relations (France)

Annie-Florence Loyer / Nadège Le Lezec

+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59

afloyer@yucatan.fr

College Hill

Media relations (Outside France)

Melanie Toyne Sewell / Donia Al Saffar

+44 (0) 207 457 2020

nanobiotix@collegehill.com